R&D A new approach to drug design: Restoring the effectiveness o... None of us are unaware of the very real danger of ‘superbugs’ – only last month, the hospita
Views & Analysis AMR: How pharma is leading the charge against superbugs GPs being sent warning letters and the World Health Organization’s World Vaccinations Week have brought the spectre of antimicrobial resistance (AMR) back into the headlines of late.
News argenx's Forte acquisition delivers coeliac trial win argenx's CD122 inhibitor FB102, added to its pipeline through the $2.2bn acquisition of Forte, is moving into phase 3 testing for coeliac disease.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
